Sage Therapeutics (SAGE) Competitors $8.68 0.00 (0.00%) As of 07/31/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SAGE vs. BHC, OCUL, AGIO, DNLI, IDYA, TARS, IRON, HRMY, MESO, and CGONShould you be buying Sage Therapeutics stock or one of its competitors? The main competitors of Sage Therapeutics include Bausch Health Cos (BHC), Ocular Therapeutix (OCUL), Agios Pharmaceuticals (AGIO), Denali Therapeutics (DNLI), IDEAYA Biosciences (IDYA), Tarsus Pharmaceuticals (TARS), Disc Medicine (IRON), Harmony Biosciences (HRMY), Mesoblast (MESO), and CG Oncology (CGON). These companies are all part of the "pharmaceutical products" industry. Sage Therapeutics vs. Its Competitors Bausch Health Cos Ocular Therapeutix Agios Pharmaceuticals Denali Therapeutics IDEAYA Biosciences Tarsus Pharmaceuticals Disc Medicine Harmony Biosciences Mesoblast CG Oncology Sage Therapeutics (NASDAQ:SAGE) and Bausch Health Cos (NYSE:BHC) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, dividends, earnings, valuation, profitability, risk and institutional ownership. Which has more risk and volatility, SAGE or BHC? Sage Therapeutics has a beta of 0.26, suggesting that its stock price is 74% less volatile than the S&P 500. Comparatively, Bausch Health Cos has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500. Do institutionals and insiders hold more shares of SAGE or BHC? 99.2% of Sage Therapeutics shares are owned by institutional investors. Comparatively, 78.7% of Bausch Health Cos shares are owned by institutional investors. 5.5% of Sage Therapeutics shares are owned by company insiders. Comparatively, 8.1% of Bausch Health Cos shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Is SAGE or BHC more profitable? Bausch Health Cos has a net margin of 0.99% compared to Sage Therapeutics' net margin of -427.78%. Sage Therapeutics' return on equity of -67.10% beat Bausch Health Cos' return on equity.Company Net Margins Return on Equity Return on Assets Sage Therapeutics-427.78% -67.10% -58.42% Bausch Health Cos 0.99%-852.36%5.25% Which has better earnings & valuation, SAGE or BHC? Bausch Health Cos has higher revenue and earnings than Sage Therapeutics. Sage Therapeutics is trading at a lower price-to-earnings ratio than Bausch Health Cos, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSage Therapeutics$41.24M13.18-$400.67M-$4.89-1.78Bausch Health Cos$9.63B0.31-$46M$0.2631.48 Do analysts rate SAGE or BHC? Sage Therapeutics presently has a consensus price target of $7.85, suggesting a potential downside of 9.56%. Bausch Health Cos has a consensus price target of $9.00, suggesting a potential upside of 9.96%. Given Bausch Health Cos' stronger consensus rating and higher possible upside, analysts plainly believe Bausch Health Cos is more favorable than Sage Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sage Therapeutics 1 Sell rating(s) 13 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.93Bausch Health Cos 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media prefer SAGE or BHC? In the previous week, Bausch Health Cos had 12 more articles in the media than Sage Therapeutics. MarketBeat recorded 13 mentions for Bausch Health Cos and 1 mentions for Sage Therapeutics. Sage Therapeutics' average media sentiment score of 1.88 beat Bausch Health Cos' score of 1.09 indicating that Sage Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Sage Therapeutics Very Positive Bausch Health Cos Positive SummaryBausch Health Cos beats Sage Therapeutics on 11 of the 15 factors compared between the two stocks. Get Sage Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SAGE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SAGE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SAGE vs. The Competition Export to ExcelMetricSage TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$543.54M$3.14B$5.70B$9.81BDividend YieldN/A2.23%4.61%4.07%P/E Ratio-1.7820.7530.6225.55Price / Sales13.18367.71465.58116.50Price / CashN/A43.0338.2159.48Price / Book1.478.659.026.15Net Income-$400.67M-$54.65M$3.25B$264.98M7 Day PerformanceN/A6.66%4.83%2.81%1 Month Performance-5.34%9.59%6.81%3.20%1 Year Performance4.58%14.32%30.56%25.33% Sage Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SAGESage Therapeutics3.9326 of 5 stars$8.68flat$7.85-9.6%N/A$543.54M$41.24M-1.78690Positive NewsBHCBausch Health Cos3.9755 of 5 stars$6.68+16.1%$9.00+34.8%+35.8%$2.13B$9.63B25.6820,700News CoveragePositive NewsInsider TradeOptions VolumeGap UpHigh Trading VolumeOCULOcular Therapeutix4.0965 of 5 stars$12.56+2.9%$17.20+36.9%+58.3%$2.12B$63.72M-9.81230AGIOAgios Pharmaceuticals4.3991 of 5 stars$35.10-1.8%$56.33+60.5%-17.9%$2.08B$36.50M3.19390Insider TradeDNLIDenali Therapeutics4.1852 of 5 stars$13.91-0.3%$33.85+143.3%-35.7%$2.03B$330.53M-5.21430Trending NewsEarnings ReportAnalyst RevisionIDYAIDEAYA Biosciences4.454 of 5 stars$22.84-1.1%$48.09+110.6%-33.7%$2.02B$7M-6.0380TARSTarsus Pharmaceuticals1.7911 of 5 stars$50.07+4.6%$66.67+33.1%+103.1%$2.02B$182.95M-21.4950News CoverageInsider TradeGap UpIRONDisc Medicine3.26 of 5 stars$58.59+1.0%$95.73+63.4%+34.0%$2.01BN/A-13.1130HRMYHarmony Biosciences4.5058 of 5 stars$34.80+1.8%$51.00+46.6%+6.0%$1.97B$714.73M11.23200MESOMesoblast2.4487 of 5 stars$14.70-2.2%$18.00+22.4%+145.1%$1.92B$5.90M0.0080Gap UpCGONCG Oncology1.3485 of 5 stars$23.94-3.7%$55.30+131.0%-21.9%$1.89B$1.14M0.0061Earnings ReportAnalyst Revision Related Companies and Tools Related Companies Bausch Health Cos Competitors Ocular Therapeutix Competitors Agios Pharmaceuticals Competitors Denali Therapeutics Competitors IDEAYA Biosciences Competitors Tarsus Pharmaceuticals Competitors Disc Medicine Competitors Harmony Biosciences Competitors Mesoblast Competitors CG Oncology Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SAGE) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sage Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sage Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access